Ipamorelin

Ipamorelin

Ipamorelin (also known as ipamorelin acetate) is a selective GHS-R1a agonist pentapeptide that stimulates pulsatile growth hormone release without significantly elevating cortisol, prolactin, or appetite-related signals. Licensed practitioners interested to buy Ipamorelin can contact Medical Spa Rx’s professional support team for guidance on sourcing from qualified suppliers and for access to supporting documentation, including purity information. This page provides an overview of Ipamorelin and its research applications through the sections and FAQ below.

Ipamorelin Benefits: Lean Muscle Mass, Weight Loss & GH Optimization

Ipamorelin is a synthetic pentapeptide GHS-R agonist first characterized by Raun and colleagues in the European Journal of Endocrinology in 1998 [1]. It binds GHS-R1a on anterior pituitary somatotrophs and stimulates pulsatile growth hormone release without significantly elevating ACTH, cortisol, prolactin, FSH, LH, or TSH in published models [1]. This selectivity distinguishes it from earlier GHRPs such as GHRP-2 and GHRP-6, which activate broader neuroendocrine pathways in addition to GH release. It is not FDA-approved for any indication and is classified as a research compound only.

Practitioner-reported applications and their evidence tiers:

• Lean muscle mass support (mechanistic rationale; practitioner-reported): Pulsatile GH release may support hepatic IGF-1 production. IGF-1 signaling is associated with PI3K/Akt/mTOR activation, protein synthesis, and satellite cell activity. Direct human RCT evidence for Ipamorelin-specific lean muscle endpoints is absent.
• Body composition and weight loss (preclinical; extrapolated from GH physiology): GH is associated with adipose tissue lipolysis via hormone-sensitive lipase activity. Dedicated human trials evaluating Ipamorelin for fat loss or body weight outcomes have not been completed.
• Recovery and sleep quality (practitioner-reported): Pre-sleep dosing is often discussed in relation to nocturnal GH secretion patterns. No controlled human data specific to Ipamorelin recovery endpoints are available.

Unlike GHRP-6, which can stimulate ghrelin-like appetite pathways through NPY/AgRP activation, Ipamorelin does not appear to significantly increase appetite at GH-releasing doses [1]. For body composition protocols, this appetite-neutral profile reduces a meaningful confounding variable.

How Ipamorelin Works: Selective GHS-R Mechanism & Ipamorelin CJC-1295 Stack

Ipamorelin’s defining feature is its selectivity [1]. In published characterization models, it produced GH release without the ACTH and cortisol elevations observed with GHRP-6 and GHRP-2. Older GHRPs stimulate GH but can also activate secondary neuroendocrine pathways; GHRP-6, for example, can increase ACTH and cortisol through AVP-stimulated mechanisms. Ipamorelin’s receptor engagement avoids that secondary cascade while preserving pulsatile GH release, producing a cleaner secretagogue signal for longer-cycle research protocols [1].

Ipamorelin CJC-1295 Combination: Complementary Receptor Architecture

The Ipamorelin and CJC-1295 combination is commonly used because the two compounds act through distinct receptors and intracellular pathways [4]:

• Ipamorelin binds GHS-R1a [4] and triggers the IP₃/DAG (inositol 1,4,5-trisphosphate/diacylglycerol) signaling cascade [4]. This pathway mobilizes intracellular calcium stores, driving pulsatile exocytosis of growth hormone while simultaneously reducing hypothalamic somatostatin inhibition.
• CJC-1295 acts as a GHRH analog at the GHRH receptor, stimulating the Gs-adenylyl cyclase-cAMP-PKA pathway to expand the overall pool of releasable growth hormone and increase pulse amplitude and duration.

The two pathways converge at the pituitary without duplicating each other. Practitioners looking to buy CJC-1295 for combination protocols should note that its cAMP-driven mechanism is fundamentally distinct from Ipamorelin’s GHS-R1a/IP₃/DAG-driven GH release [4]. Ipamorelin should not be conflated with GHRH analogs such as CJC-1295 or Sermorelin; they act through different receptor classes, intracellular pathways, and protocols.

Ipamorelin Dosage, Storage & Administration

Practitioner-reported Ipamorelin protocols describe subcutaneous administration at 100–300 mcg per dose, typically 2–3 times daily or before sleep. Pre-sleep timing is often discussed because it aligns with the body’s natural nocturnal GH secretion window. All dosing references are practitioner-reported only. No FDA-validated Ipamorelin dosing protocol exists.

Additional handling considerations:

• Reconstitution: Bacteriostatic water, per standard peptide handling
• Storage: 2–8°C post-reconstitution; protect from light; use within the stability window specified in supplier documentation
• CJC-1295 combination timing: Because CJC-1295 with DAC has a much longer activity window than Ipamorelin, the two are generally discussed on separate schedules and should not be automatically co-administered without a clear protocol rationale

Ipamorelin Side Effects, Safety & Legal Status

Ipamorelin is often described as having one of the cleaner adverse event profiles in the GH secretagogue class. That characterization is based on preclinical data, limited human pharmacokinetic and pharmacodynamic work, and practitioner-reported experience [2] — not long-term human RCT data.

Commonly discussed considerations:

• Injection site reactions: Mild localized redness, tenderness, or transient swelling; typically mild and self-limiting
• Water retention: Mild and transient in practitioner-reported protocols; likely related to downstream GH/IGF-1 axis activity
• Cortisol and prolactin: No significant elevations at GH-releasing doses in published models [1] — the key differentiator from less selective GHRPs
• Long-term safety: No long-term human body composition RCT has established Ipamorelin’s safety or efficacy for that purpose [2]. Novo Nordisk advanced Ipamorelin into Phase II for postoperative ileus [2]; the program did not reach regulatory approval.

Current Regulatory and Legal Status

• United States: Not FDA-approved for any indication; not listed on the FDA 503A compounding list. Research compound only.
• Australia: Not TGA-approved.
• WADA: Growth hormone secretagogues, including GHS-R agonists, are prohibited in-competition under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) [3]. Licensed professionals working with competitive athletes should communicate this restriction clearly.

All regulatory details are subject to change [3]. Verify current status within the relevant jurisdiction before any protocol consideration.

Ipamorelin vs CJC-1295 & Ipamorelin vs Sermorelin

Ipamorelin and CJC-1295 are better understood as complementary tools than direct substitutes. Ipamorelin acts through GHS-R1a [5], triggering pulsatile GH release via the IP₃/DAG pathway and intracellular calcium mobilization, while CJC-1295 acts through the GHRH receptor via the cAMP-PKA pathway to expand the releasable GH pool and extend pulse amplitude [5]. In practical terms, Ipamorelin initiates the GH pulse while CJC-1295 supports its amplitude and duration. Ipamorelin monotherapy may be preferred when the protocol calls for isolated GHS-R1a-driven pulsatility without broader axis engagement. The combination is more relevant when the objective requires a stronger pulse amplitude or systemic IGF-1 support. Practitioners considering whether to buy CJC-1295 as part of a stacked protocol should review both compound profiles to confirm that the mechanisms are complementary within their specific research design.

Meanwhile, Ipamorelin and Sermorelin operate through different receptor systems and should not be treated as simple substitutes. Sermorelin is a GHRH(1-29) analog that acts at the GHRH receptor via cAMP-mediated signaling, whereas Ipamorelin acts at GHS-R1a via the IP₃/DAG pathway [5]. Sermorelin has a short half-life of approximately 10–20 minutes and requires daily nightly dosing; it may be more appropriate when the protocol specifically calls for GHRH receptor activation. Ipamorelin is more relevant when the goal is selective GHS-R1a-driven GH pulsatility without cortisol, prolactin, or appetite-related confounders — a meaningful distinction for longer-cycle protocols. Practitioners who buy Sermorelin for GHRH receptor-based protocols will find the two compounds occupy distinct roles, and the choice between them depends on which receptor axis the research design requires.

Where Can Practitioners Buy Ipamorelin Online?

Ipamorelin is available for research purposes only to qualified licensed professionals. When buying online, practitioners should source exclusively from suppliers with verifiable purity documentation, including a certificate of analysis (COA), LOT number traceability, and clear handling and storage specifications. Those looking to check for wholesale buying options should confirm that any supplier meets these documentation standards before proceeding.

Medical Spa Rx’s professional support team offers sourcing guidance and access to supporting documentation for licensed practitioners evaluating research-grade Ipamorelin. For guidance on supplier qualification, purity records, and compliance considerations, contact the professional support team directly.

FAQs

1. What is Ipamorelin used for?

Ipamorelin is a selective GHS-R1a agonist pentapeptide discussed in practitioner-reported protocols for GH optimization, support for lean muscle mass, body composition, recovery, and natural growth hormone production. It stimulates pulsatile GH release from the anterior pituitary and is often paired with CJC-1295. It is not FDA-approved for any indication and is classified as a research compound only.

2. What does Ipamorelin do — does it raise cortisol or prolactin?

Ipamorelin binds GHS-R1a on pituitary somatotrophs and stimulates pulsatile GH release through the IP₃/DAG pathway, which mobilizes intracellular calcium for vesicle release [4]. Unlike less selective GHRPs such as GHRP-2 and GHRP-6, Ipamorelin does not significantly elevate ACTH, cortisol, or prolactin in published characterization models [1]. This clean selectivity is its defining differentiator within the GH secretagogue class.

3. Does Ipamorelin increase appetite?

Ipamorelin does not appear to significantly increase appetite at GH-releasing doses [1]. This separates it from GHRP-6, which can stimulate ghrelin-like appetite pathways through NPY/AgRP signaling. For body composition protocols, Ipamorelin’s appetite-neutral profile reduces confounding due to variability in caloric intake.

4. What is the Ipamorelin dosage?

Practitioner-reported protocols describe Ipamorelin at 100–300 mcg per subcutaneous dose, 2–3 times daily or before sleep. When paired with CJC-1295, Ipamorelin is discussed on its own schedule due to its shorter activity window. These are not FDA-validated protocols and require individualized professional assessment.

5. What are the Ipamorelin benefits?

Mechanistically supported and practitioner-reported applications include GH optimization, support for lean muscle mass, body composition, recovery, and sleep-adjacent protocols. The rationale draws on GH/IGF-1 axis biology, including protein synthesis, lipolysis, and tissue repair signaling. Dedicated human RCT data for Ipamorelin-specific body composition outcomes are absent.

6. What are the Ipamorelin side effects?

Commonly discussed effects include mild injection site reactions and transient water retention. Published characterization data support Ipamorelin’s selective profile, with no significant elevations in cortisol or prolactin at GH-releasing doses [1]. Long-term human safety data remain limited [2], and protocol discussions should remain conservative.

7. Where can practitioners buy Ipamorelin?

Licensed professionals evaluating where to buy Ipamorelin wholesale should review supplier qualification, purity documentation, and applicable regulatory status. Medical Spa Rx’s professional support team can provide guidance on sourcing from qualified suppliers and access to supporting documentation, including certificates of analysis.

Sources

1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:1530/eje.0.1390552
2. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. doi:10.1007/s00384-014-2030-8
3. World Anti-Doping Agency. 2026 International Standard Prohibited List. Published April 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
4. Muccioli G, Baragli A, Granata R, Papotti M, Ghigo E. Heterogeneity of ghrelin/growth hormone secretagogue receptors. Toward the understanding of the molecular identity of novel ghrelin/GHS receptors. Neuroendocrinology. 2007;86(3):147-164. doi:10.1159/000105141

The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.